

April 5, 2020

The World Journal of Clinical Cases

Revision of our manuscript: Serum vWF for early diagnosis of lung adenocarcinoma in patients with T2DM (manuscript number: 54643)

Dear Editor,

Thank you very much for the careful review of our manuscript entitled, “Serum vWF for early diagnosis of lung adenocarcinoma in patients with T2DM” (manuscript number: 54643) and for your potential interest. We have addressed the comments and suggestions provided by the reviewer, and a point-by-point response to the comments can be found in the attached response letter.

We hope the editors and reviewers will find the revised manuscript suitable for publication in *The World Journal of Clinical Cases*.

Sincerely yours,

Bimin Shi, MD

The First Affiliated Hospital of Soochow University, China

Email: gtmake144523@163.com

Responses to Reviewers:

Reviewer #1 (Comments to the author)

Authors reported well-balanced manuscript with clear aim and interesting results. The aim of the study was to investigate the clinical value of serum vWF as a tumor marker in patients with T2DM combined with lung adenocarcinoma. The main finding of the study was follow: serum levels of vWF in patients with T2DM combined with lung AIS were significantly higher than T2DM patients. This finding deserves to be published, but there is minor concern regarding conclusive part. Authors have defined that "Serum vWF level may represent a novel biomarker for the early diagnosis of lung AIS", but they did not investigate predictive ability of the biomarker. I recommend authors to modify the conclusive part giving assumptions in the section "Discussion"

Response: Thank you very much for your positive comments and suggestions. We agree that we did not investigate the predictive ability of the biomarker. According to your suggestion, we have now modified the conclusion part in the Discussion to state: “Thus, monitoring serum vWF might promote the early diagnosis of lung AIS in T2DM patients.”

Language Quality: Grade B (Minor language polishing)

Response: Thank you very much for your suggestions. The manuscript has now been proofread and edited by *Medjaden Bioscience Limited*. Please find the English Editing Certificate in the submission files, and we hope you find the language satisfactory.